Inspire Medical Systems adds AtriCure CEO Michael Carrel to board in July 20 appointment
A board seat at Inspire Medical Systems (NYSE: INSP) is in focus after the company's directors named Michael H. Carrel, the sitting president and chief executive of AtriCure, Inc. (NASDAQ: ATRC), as a Class III director on July 20, 2026. The 8-K hit the tape July 24. His term runs through the 2027 Annual Meeting of Stockholders, at which point his seat comes up for renewal.
Key takeaways
- Inspire Medical Systems (NYSE: INSP) appointed AtriCure president and CEO Michael H. Carrel as a Class III director on July 20, 2026, with the 8-K filed July 24, 2026.
- Carrel's board term runs through the 2027 Annual Meeting of Stockholders, when his Class III seat is subject to renewal.
- Carrel, age 55, was assigned to Inspire's Organization and Compensation Committee and its Quality, Product Supply and Technology Committee.
- Carrel receives a $55,000 annual cash retainer, an additional $7,500 for each of his two committee assignments, an initial RSU award valued at $300,000 vesting over three years, and $200,000 annual RSU grants thereafter.
- No guidance revision, product update or strategic announcement accompanied the filing.
A board seat at Inspire Medical Systems (NYSE: INSP) is in focus after the company's directors named Michael H. Carrel, the sitting president and chief executive of AtriCure, Inc. (NASDAQ: ATRC), as a Class III director on July 20, 2026. The 8-K hit the tape July 24. His term runs through the 2027 Annual Meeting of Stockholders, at which point his seat comes up for renewal.
Carrel's background and committee assignments
Carrel, age 55, joined the Inspire board with assignments to two committees: Organization and Compensation, and Quality, Product Supply and Technology. The Nominating and Corporate Governance Committee recommended the appointment. His most visible current role is at AtriCure, where he has served as president, CEO and director since November 2012. AtriCure develops device-based solutions for atrial fibrillation, left atrial appendage management and post-operative pain management.
Before AtriCure, Carrel was president and CEO of Vital Images, a publicly traded medical imaging software company acquired by Toshiba Medical Systems Corporation. He also held the president and CEO role at Zamba Corporation, a publicly traded technology company, and served as chief financial officer of NextNet Wireless.
Prior public-company board experience includes Axonics, Inc., where he sat from February 2019 through November 2024 and held the chairman seat beginning April 2020. Boston Scientific subsequently acquired Axonics. Outside medical devices, Carrel has chaired Big Brothers Big Sisters of America since 2021 and has sat on the Medical Device Manufacturers Association board since 2017. He holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
Compensation terms
Under Inspire's Non-Employee Director Compensation Policy, Carrel is eligible for an annual cash retainer of $55,000 for board service. Each of his two committee assignments carries an additional $7,500 annual retainer, earned quarterly.
On the equity side, the initial restricted stock unit award carries an aggregate fair value of $300,000, vesting in equal annual installments over three years from the grant date. Annual RSU grants thereafter carry an aggregate fair value of $200,000, each vesting on the first anniversary of the respective grant date. Carrel may take any portion of his cash retainers in Inspire common stock instead of cash.
What to watch
No guidance revision, product update or strategic announcement accompanied the filing. Bryan K. Phillips, Sr. Vice President, General Counsel and Secretary, signed the 8-K on July 24. The next confirmable date on the tape: the 2027 Annual Meeting of Stockholders, when Carrel's Class III seat is subject to renewal.
Related reading
Filed by the macro desk of MarketPR on July 24, 2026. Source: sec.gov. Indicative figures are not investment advice.